DEBIO-1562
- Generic Name
- DEBIO-1562
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Phase 2
Completed
- Conditions
- B-cell Non-Hodgkin's LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 100
- Registration Number
- NCT02564744
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- Lymphoma, Non-HodgkinChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01534715
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath